Vancomycin is a commonly utilized empiric therapy for patients with hospital-acquired and healthcare-associated pneumonia (HAP and HCAP). De-escalation is encouraged in the guidelines but not commonly performed in the absence of culture data. Studies have shown that in certain low-risk patients, vancomycin may not be necessary. A clinical criterion document was implemented in 2018 at CHI Memorial to facilitate rapid de-escalation of vancomycin. This study aims to assess the impact of early discontinuation of vancomycin in patients with HAP or HCAP and no respiratory culture.
